Cargando…

The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China

BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yezhou, Feng, Mingyang, Ma, Di, Zhao, Gangde, Wang, Xiaolin, An, Baoyan, Xu, Yumin, Lou, Shike, Lin, Lanyi, Xie, Qing, Liu, Kehui, Bao, Shisan, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043326/
https://www.ncbi.nlm.nih.gov/pubmed/36998463
http://dx.doi.org/10.3389/fonc.2023.1109980
_version_ 1784913121396129792
author Ding, Yezhou
Feng, Mingyang
Ma, Di
Zhao, Gangde
Wang, Xiaolin
An, Baoyan
Xu, Yumin
Lou, Shike
Lin, Lanyi
Xie, Qing
Liu, Kehui
Bao, Shisan
Wang, Hui
author_facet Ding, Yezhou
Feng, Mingyang
Ma, Di
Zhao, Gangde
Wang, Xiaolin
An, Baoyan
Xu, Yumin
Lou, Shike
Lin, Lanyi
Xie, Qing
Liu, Kehui
Bao, Shisan
Wang, Hui
author_sort Ding, Yezhou
collection PubMed
description BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients. RESULTS: The average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05). CONCLUSIONS: It was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs.
format Online
Article
Text
id pubmed-10043326
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100433262023-03-29 The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China Ding, Yezhou Feng, Mingyang Ma, Di Zhao, Gangde Wang, Xiaolin An, Baoyan Xu, Yumin Lou, Shike Lin, Lanyi Xie, Qing Liu, Kehui Bao, Shisan Wang, Hui Front Oncol Oncology BACKGROUND: The clinical characteristics of primary liver cancer (PLC) patients are changing, maybe due to hepatitis viral vaccination and lifestyle changes, etc. The linkage between these changes and outcomes among these PLCs has not yet been fully elucidated. METHODS: It was identified total of 1691 PLC cases diagnosed between 2000 ~ 2020. Cox proportional hazards models were utilized to determine the connections between the clinical presentations and their close risk factor(s) from PLC patients. RESULTS: The average age of PLC patients increased gradually from 52.74 ± 0.5 years in 2000 ~ 2004 to 58.63 ± 0.44 years in 2017 ~ 2020, accompanied by an increased proportion of females from 11.11% to 22.46%, and non-viral hepatitis-related PLC was raised from 1.5% to 22.35%. 840 (49.67%) PLC patients with alpha-fetoprotein (AFP) < 20ng/mL (AFP-negative). The mortality was 285 (16.85%) or 532 (31.46%) PLC patients with alanine transaminase (ALT) between 40 ~ 60 IU/L or ALT > 60 IU/L. The PLC patients with pre-diabetes/diabetes or dyslipidemia also increased from 4.29% or 11.1% in 2000 ~ 2004 to 22.34% or 46.83% in 2017 ~ 2020. The survival period of the PLC patients with normoglycemia or normolipidemic was 2.18 or 3.14 folds longer than those patients with pre-diabetes/diabetes or hyperlipidemia (P<0.05). CONCLUSIONS: It was gradually increased that age, the proportion of females, non-viral hepatitis-related causes, AFP-negative, and abnormal glucose/lipids among PLC patients. Proper control of glucose/lipids or ALT may improve the prognosis of PLCs. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043326/ /pubmed/36998463 http://dx.doi.org/10.3389/fonc.2023.1109980 Text en Copyright © 2023 Ding, Feng, Ma, Zhao, Wang, An, Xu, Lou, Lin, Xie, Liu, Bao and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ding, Yezhou
Feng, Mingyang
Ma, Di
Zhao, Gangde
Wang, Xiaolin
An, Baoyan
Xu, Yumin
Lou, Shike
Lin, Lanyi
Xie, Qing
Liu, Kehui
Bao, Shisan
Wang, Hui
The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title_full The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title_fullStr The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title_full_unstemmed The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title_short The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China
title_sort 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from china
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043326/
https://www.ncbi.nlm.nih.gov/pubmed/36998463
http://dx.doi.org/10.3389/fonc.2023.1109980
work_keys_str_mv AT dingyezhou the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT fengmingyang the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT madi the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT zhaogangde the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT wangxiaolin the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT anbaoyan the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT xuyumin the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT loushike the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT linlanyi the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT xieqing the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT liukehui the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT baoshisan the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT wanghui the20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT dingyezhou 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT fengmingyang 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT madi 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT zhaogangde 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT wangxiaolin 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT anbaoyan 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT xuyumin 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT loushike 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT linlanyi 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT xieqing 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT liukehui 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT baoshisan 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina
AT wanghui 20yearstransitionofclinicalcharacteristicsandmetabolicriskfactorsinprimarylivercancerpatientsfromchina